AU2021234601A1 - Atomized inhalation formulation containing human cell-derived extracellular vesicles, preparation method and use thereof - Google Patents

Atomized inhalation formulation containing human cell-derived extracellular vesicles, preparation method and use thereof Download PDF

Info

Publication number
AU2021234601A1
AU2021234601A1 AU2021234601A AU2021234601A AU2021234601A1 AU 2021234601 A1 AU2021234601 A1 AU 2021234601A1 AU 2021234601 A AU2021234601 A AU 2021234601A AU 2021234601 A AU2021234601 A AU 2021234601A AU 2021234601 A1 AU2021234601 A1 AU 2021234601A1
Authority
AU
Australia
Prior art keywords
cells
extracellular vesicles
pharmaceutical composition
peg
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021234601A
Other languages
English (en)
Inventor
Yinglu CHEN
Chengxiang DAI
Jigang LEI
Ping Li
Suke LI
Xiaole SONG
Jing Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellular Biopharma Shanghai Ltd
Original Assignee
Cellular Biopharma Shanghai Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellular Biopharma Shanghai Ltd filed Critical Cellular Biopharma Shanghai Ltd
Publication of AU2021234601A1 publication Critical patent/AU2021234601A1/en
Assigned to Cellular Biopharma (Shanghai), Ltd. reassignment Cellular Biopharma (Shanghai), Ltd. Request for Assignment Assignors: CELLULAR BIOMEDICINE GROUP (SHANGHAI) LTD., CELLULAR BIOMEDICINE GROUP (WUXI) LTD.
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/50—Soluble polymers, e.g. polyethyleneglycol [PEG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
AU2021234601A 2020-03-13 2021-03-15 Atomized inhalation formulation containing human cell-derived extracellular vesicles, preparation method and use thereof Pending AU2021234601A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010177541.7 2020-03-13
CN202010177541.7A CN113384597A (zh) 2020-03-13 2020-03-13 含人体细胞衍生的细胞膜外囊泡的雾化吸入制剂、制法及其应用
PCT/CN2021/080869 WO2021180237A1 (zh) 2020-03-13 2021-03-15 含人体细胞衍生的细胞膜外囊泡的雾化吸入制剂、制法及其应用

Publications (1)

Publication Number Publication Date
AU2021234601A1 true AU2021234601A1 (en) 2022-10-06

Family

ID=77616331

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021234601A Pending AU2021234601A1 (en) 2020-03-13 2021-03-15 Atomized inhalation formulation containing human cell-derived extracellular vesicles, preparation method and use thereof

Country Status (6)

Country Link
US (1) US20230120324A1 (https=)
EP (1) EP4134105A4 (https=)
JP (1) JP2023516458A (https=)
CN (1) CN113384597A (https=)
AU (1) AU2021234601A1 (https=)
WO (1) WO2021180237A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230050813A1 (en) 2020-01-13 2023-02-16 Carmine Therapeutics Pte. Ltd. Nucleic acid loaded red blood cell extracellular vesicles
CN115212230B (zh) * 2021-04-21 2024-12-27 时比曼生物科技(上海)有限公司 含有干细胞胞外囊泡的药物组合物及其在呼吸道炎症治疗中的应用
CN114306621B (zh) * 2021-12-20 2023-10-20 苏州大学 一种携带核酸药物的细胞外泌体及其制备方法与在免疫治疗中的应用
WO2023123216A1 (zh) * 2021-12-30 2023-07-06 中山大学 囊泡在制备治疗肺部疾病的药物中的应用
CN114480260B (zh) * 2022-01-24 2024-02-09 同济大学 一种成体肺干细胞外泌体及其制备方法和应用
CN114099481B (zh) * 2022-01-28 2022-05-24 深圳湾实验室 雾化吸入型糖皮质激素纳米药物及其制备方法和应用
CN114432341B (zh) * 2022-02-18 2024-02-06 徐州医科大学 一种用于预防和治疗高原肺水肿的间充质干细胞杂化胞外囊泡的制备方法
CN114652703B (zh) * 2022-03-14 2023-07-04 陕西兰医维生物科技有限公司 雾化吸入功能性细胞外囊泡在改善急性肺损伤中的应用
CN115414387A (zh) * 2022-08-12 2022-12-02 四川大学华西医院 一种用于治疗肺纤维化的医疗包
WO2024118073A1 (en) * 2022-11-30 2024-06-06 Carmine Therapeutics Pte. Ltd. Pulmonary delivery of nebulized preparations of red blood cell extracellular vesicles (rbcevs)
US11944742B1 (en) * 2023-06-08 2024-04-02 Microneb Tech Holdings, Inc. Apparatus, methods, and systems for administering a medication to an animal
JP7730003B2 (ja) * 2023-02-10 2025-08-27 中国▲医▼薬大学 細胞外小胞／エクソソーム保存溶液及びその混合溶液
CN119097599B (zh) * 2024-09-09 2025-04-18 北京青藤谷禧干细胞科技研究院有限公司 一种含干细胞外泌体的雾化剂及其制备方法和应用
CN119606929A (zh) * 2024-12-02 2025-03-14 浙江大学 一种基于细胞膜的载核酸药物生物囊泡吸入制剂的制备方法及其产品和应用
CN120284902A (zh) * 2025-04-29 2025-07-11 洛阳市中心医院 一种仿生囊泡制剂及其制备方法与应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5667180B2 (ja) * 2009-07-01 2015-02-12 イオン メディックス インコーポレイテッド 哺乳類の有核細胞に由来するマイクロベシクル及びその用途
CA2829586C (en) * 2011-03-11 2021-03-02 Children's Medical Center Corporation Methods and compositions relating to mesenchymal stem cell exosomes
CN105209881B (zh) * 2013-03-13 2021-01-22 迈阿密大学 从细胞培养上清液和生物流体分离并纯化微泡的方法
US10143709B2 (en) * 2014-05-06 2018-12-04 Indiana University Research And Technology Corporation Use of ASC and ASC-CM to treat ARDS, SARS, and MERS
CN105267240B (zh) * 2014-12-16 2019-05-14 天津医科大学眼科医院 间充质干细胞来源的外泌体的用途
CN105796599A (zh) * 2014-12-29 2016-07-27 西比曼生物科技（上海）有限公司 一种用于治疗哮喘的脂肪间充质祖细胞复合物
EP3270984A4 (en) * 2015-03-16 2019-04-17 Duncan Ross TREATMENT METHOD WITH MEMBRANE-INCLUDED VESICLE
WO2018071677A1 (en) * 2016-10-13 2018-04-19 Vbc Holdings Llc Medical uses of exosomes
CN110072991A (zh) * 2016-10-13 2019-07-30 Vbc控股有限责任公司 来源于发炎的细胞或组织的抗炎外泌体
WO2018109525A1 (en) * 2016-12-14 2018-06-21 Università Degli Studi Di Padova New anti-angiogenic extracellurlar vesicles
CN107137426A (zh) * 2017-05-17 2017-09-08 天津普瑞赛尔生物科技有限公司 含人间充质干细胞外泌体提取物的矽肺病治疗雾化剂及其制备方法
CA3072562A1 (en) * 2017-08-15 2019-02-21 Children's Medical Center Corporation Purified mesenchymal stem cell exosomes and uses thereof
CN109419770A (zh) * 2018-03-07 2019-03-05 厦门艾赛生物科技有限公司 一种间充质干细胞外泌体滴眼液及其制备方法和应用
MA53273A (fr) * 2018-08-10 2021-06-16 Omnispirant Ltd Vésicules extracellulaires pour inhalation
CN109432130A (zh) * 2018-12-20 2019-03-08 中科广聚(北京)生物医学技术中心有限公司 间充质干细胞外泌体在制备预防和治疗放射性肺损伤的药物中的应用
EP4179069A4 (en) * 2020-07-09 2024-10-02 Remedy Cell Ltd. METHODS FOR THE TREATMENT OF ACUTE RESPIRATORY INFLAMMATION AND CYTOKINE STORM SYNDROME
WO2022018729A1 (en) * 2020-07-20 2022-01-27 Brainstorm Cell Therapeutics Ltd. Methods and compositions for treating lung conditions

Also Published As

Publication number Publication date
EP4134105A1 (en) 2023-02-15
US20230120324A1 (en) 2023-04-20
WO2021180237A1 (zh) 2021-09-16
JP2023516458A (ja) 2023-04-19
EP4134105A4 (en) 2024-05-15
CN113384597A (zh) 2021-09-14

Similar Documents

Publication Publication Date Title
US20230120324A1 (en) Atomized inhalation formulation containing human cell-derived extracellular vesicles, preparation method and use thereof
Chen et al. Transplantation of adipose-derived mesenchymal stem cells attenuates pulmonary fibrosis of silicosis via anti-inflammatory and anti-apoptosis effects in rats
Wang et al. Peritoneal M2 macrophage-derived extracellular vesicles as natural multitarget nanotherapeutics to attenuate cytokine storms after severe infections
CN105861430B (zh) 一种外泌体、外泌体的制备方法及其在制备治疗脓毒症药物或者制剂中的应用
Wu et al. Neutrophil membrane engineered HucMSC sEVs alleviate cisplatin-induced AKI by enhancing cellular uptake and targeting
CN115212230B (zh) 含有干细胞胞外囊泡的药物组合物及其在呼吸道炎症治疗中的应用
RU2715866C2 (ru) Мезенхимальные стромальные клетки для лечения синдрома сепсиса
EP4181935A1 (en) Methods and compositions for treating lung conditions
CN111182890A (zh) 用于治疗大疱性表皮松解症的方法和组合物
KR20200030084A (ko) 씨디39 기질 줄기세포 단리 방법 및 용도
CN113768953B (zh) 凋亡小体用于制备治疗急性肺损伤药物的应用
CN117064877B (zh) 一种包含黄芩素或其衍生物的外泌体组合物及其在治疗鼻炎中的应用
US20240247234A1 (en) Off-the-shelf human umbilical cord-derived mesenchymal stem cells and preparation method and use thereof
CN115942952A (zh) 使用来自骨髓来源的间充质干细胞的微囊泡的治疗组合物和方法
CN114652703B (zh) 雾化吸入功能性细胞外囊泡在改善急性肺损伤中的应用
CN111904980A (zh) 间充质干细胞与在治疗急性肺损伤、急性呼吸窘迫症或肺纤维化中的用途
HK40082197A (en) Atomized inhalation formulation containing human cell-derived extracellular vesicles, preparation method and use thereof
CN111437291B (zh) 功能化多能干细胞纳米囊泡制剂的制备及其在防治肺炎中的用途
CN117122614A (zh) 凋亡囊泡用于制备治疗哺乳动物视网膜新生血管药物的应用
KR20220073662A (ko) 트롬빈 처리 줄기세포에서 유래된 엑소좀을 포함하는 감염성 질환 치료용 조성물
CN112336871A (zh) 一种用于缓解肺部炎症的DiR-SPIO-ST2纳米颗粒及其制备方法
US20240374649A1 (en) Method for Treating Ilk Signaling Pathway Related Diseases Using Exosome Derived from Mesenchymal Stem Cells, and Pharmaceutical Composition
Xu et al. Effect Analysis of Extracellular Vesicles in the Treatment of Bronchopulmonary Dysplasia via Different Drug Delivery and Administration Routes
US20230405050A1 (en) Composition for treating infectious diseases, comprising exosomes derived from thrombin-treated stem cells
CN121136922A (zh) 一种间充质干细胞外泌体及其诱导培养基、制备方法、产品和应用

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CELLULAR BIOPHARMA (SHANGHAI), LTD.

Free format text: FORMER APPLICANT(S): CELLULAR BIOMEDICINE GROUP (SHANGHAI) LTD.; CELLULAR BIOMEDICINE GROUP (WUXI) LTD.